StreetInsider.com News Articles

UPDATE – Visionary Doubles Down on High-Margin Medical Aesthetics with US$12 Million Exclusive Agreement, Initiates Strategic Exit from Non-Core Businesses

Mon, 09 Mar 2026 08:30:00 -0400

HONG KONG, March 09, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“the Company”), a technology-driven multinational enterprise focused on biotechnology and healthcare, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited (“GV Hong Kong”), has signed a US$12 million exclusive distribution agreement for its flagship anti-aging product, Premier Regenerative Complex-President Super Injection, in cooperation with Huajin China Investment Company（”Huajin China”), alongside the Board-approved divestiture of its non-core business.

These strategic actions mark the Company’s formal transition into a commercialization acceleration phase within the high-end medical aesthetics sector.

Commercialization Milestone for Premier

UPDATE – Visionary Doubles Down on High-Margin Medical Aesthetics with US$12 Million Exclusive Agreement, Initiates Strategic Exit from Non-Core Businesses

Mon, 09 Mar 2026 08:30:00 -0400

HONG KONG, March 09, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“the Company”), a technology-driven multinational enterprise focused on biotechnology and healthcare, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited (“GV Hong Kong”), has signed a US$12 million exclusive distribution agreement for its flagship anti-aging product, Premier Regenerative Complex-President Super Injection, in cooperation with Huajin China Investment Company（”Huajin China”), alongside the Board-approved divestiture of its non-core business.

These strategic actions mark the Company’s formal transition into a commercialization acceleration phase within the high-end medical aesthetics sector.

Commercialization Milestone for Premier

UPDATE – Visionary Doubles Down on High-Margin Medical Aesthetics with US$12 Million Exclusive Agreement, Initiates Strategic Exit from Non-Core Businesses

Mon, 09 Mar 2026 08:30:00 -0400

HONG KONG, March 09, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“the Company”), a technology-driven multinational enterprise focused on biotechnology and healthcare, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited (“GV Hong Kong”), has signed a US$12 million exclusive distribution agreement for its flagship anti-aging product, Premier Regenerative Complex-President Super Injection, in cooperation with Huajin China Investment Company（”Huajin China”), alongside the Board-approved divestiture of its non-core business.

These strategic actions mark the Company’s formal transition into a commercialization acceleration phase within the high-end medical aesthetics sector.

Commercialization Milestone for Premier

UPDATE – Visionary Doubles Down on High-Margin Medical Aesthetics with US$12 Million Exclusive Agreement, Initiates Strategic Exit from Non-Core Businesses

Mon, 09 Mar 2026 08:30:00 -0400

HONG KONG, March 09, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“the Company”), a technology-driven multinational enterprise focused on biotechnology and healthcare, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited (“GV Hong Kong”), has signed a US$12 million exclusive distribution agreement for its flagship anti-aging product, Premier Regenerative Complex-President Super Injection, in cooperation with Huajin China Investment Company（”Huajin China”), alongside the Board-approved divestiture of its non-core business.

These strategic actions mark the Company’s formal transition into a commercialization acceleration phase within the high-end medical aesthetics sector.

Commercialization Milestone for Premier

Visionary Holdings projects $30 million sales from anti-aging line

Thu, 05 Mar 2026 09:31:36 -0400

Visionary Holdings Inc. (NASDAQ: GV) announced its business outlook for 2026-2027, projecting that its RAMU anti-aging product line could reach approximately $30 million in annual sales during this period.
The Hong Kong-based technology and healthcare company stated the projection is subject to market conditions, regulatory approvals, and operational execution. The company has been repositioning its strategic focus toward healthcare services and medical aesthetics businesses over the past year.
Visionary plans to continue expanding into North America and Europe through product commercialization, distribution partnerships, and healthcare service collaborations. The company expects these business segments to deliver higher gross margins compared to certain legacy

Visionary Holdings (NASDAQ: GV) Provides 2026–2027 Growth Outlook; RAMU Anti-Aging Product Line Targets Potential $30 Million Annual Sales

Thu, 05 Mar 2026 09:30:00 -0400

Company Continues Expansion into North America and Europe as Part of Global Medical Aesthetics Strategy
HONG KONG, March 05, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“Visionary” or the “Company”), a technology-driven multinational enterprise focused on healthcare services, medical aesthetics, and advanced biotechnology applications, today provided its 2026–2027 business outlook and strategic growth priorities as the Company continues executing its expansion into global healthcare and medical aesthetics markets.

Over the past year, Visionary has progressively repositioned its strategic focus toward higher-margin healthcare services and medical aesthetics businesses. The Company has previously announced initiatives aimed at expanding

Visionary Holdings (NASDAQ: GV) Provides 2026–2027 Growth Outlook; RAMU Anti-Aging Product Line Targets Potential $30 Million Annual Sales

Thu, 05 Mar 2026 09:30:00 -0400

Company Continues Expansion into North America and Europe as Part of Global Medical Aesthetics Strategy
HONG KONG, March 05, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“Visionary” or the “Company”), a technology-driven multinational enterprise focused on healthcare services, medical aesthetics, and advanced biotechnology applications, today provided its 2026–2027 business outlook and strategic growth priorities as the Company continues executing its expansion into global healthcare and medical aesthetics markets.

Over the past year, Visionary has progressively repositioned its strategic focus toward higher-margin healthcare services and medical aesthetics businesses. The Company has previously announced initiatives aimed at expanding

Visionary Holdings (NASDAQ: GV) Provides 2026–2027 Growth Outlook; RAMU Anti-Aging Product Line Targets Potential $30 Million Annual Sales

Thu, 05 Mar 2026 09:30:00 -0400

Company Continues Expansion into North America and Europe as Part of Global Medical Aesthetics Strategy
HONG KONG, March 05, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“Visionary” or the “Company”), a technology-driven multinational enterprise focused on healthcare services, medical aesthetics, and advanced biotechnology applications, today provided its 2026–2027 business outlook and strategic growth priorities as the Company continues executing its expansion into global healthcare and medical aesthetics markets.

Over the past year, Visionary has progressively repositioned its strategic focus toward higher-margin healthcare services and medical aesthetics businesses. The Company has previously announced initiatives aimed at expanding

Visionary Holdings (NASDAQ: GV) Provides 2026–2027 Growth Outlook; RAMU Anti-Aging Product Line Targets Potential $30 Million Annual Sales

Thu, 05 Mar 2026 09:30:00 -0400

Company Continues Expansion into North America and Europe as Part of Global Medical Aesthetics Strategy
HONG KONG, March 05, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“Visionary” or the “Company”), a technology-driven multinational enterprise focused on healthcare services, medical aesthetics, and advanced biotechnology applications, today provided its 2026–2027 business outlook and strategic growth priorities as the Company continues executing its expansion into global healthcare and medical aesthetics markets.

Over the past year, Visionary has progressively repositioned its strategic focus toward higher-margin healthcare services and medical aesthetics businesses. The Company has previously announced initiatives aimed at expanding

Visionary Doubles Down on High-Margin Medical Aesthetics with US$12 Million Exclusive Agreement, Initiates Strategic Exit from Non-Core Businesses

Mon, 02 Mar 2026 09:30:00 -0400

HONG KONG, March 02, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“the Company”), a technology-driven multinational and biotechnology and healthcare-focused company, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited (“GV Hong Kong”), today announced the signing of a US$12 million exclusive distribution agreement for its flagship anti-aging product, Premier Regenerative Complex---President Super Injection, in cooperation with Huajin China Investment Company（”Huajin China”), alongside the Board-approved divestiture of its non-core education business.

These strategic actions mark the Company’s formal transition into a commercialization acceleration phase within the high-end medical aesthetics sector.

Commercialization

Visionary Doubles Down on High-Margin Medical Aesthetics with US$12 Million Exclusive Agreement, Initiates Strategic Exit from Non-Core Businesses

Mon, 02 Mar 2026 09:30:00 -0400

HONG KONG, March 02, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“the Company”), a technology-driven multinational and biotechnology and healthcare-focused company, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited (“GV Hong Kong”), today announced the signing of a US$12 million exclusive distribution agreement for its flagship anti-aging product, Premier Regenerative Complex---President Super Injection, in cooperation with Huajin China Investment Company（”Huajin China”), alongside the Board-approved divestiture of its non-core education business.

These strategic actions mark the Company’s formal transition into a commercialization acceleration phase within the high-end medical aesthetics sector.

Commercialization

Visionary Doubles Down on High-Margin Medical Aesthetics with US$12 Million Exclusive Agreement, Initiates Strategic Exit from Non-Core Businesses

Mon, 02 Mar 2026 09:30:00 -0400

HONG KONG, March 02, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“the Company”), a technology-driven multinational and biotechnology and healthcare-focused company, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited (“GV Hong Kong”), today announced the signing of a US$12 million exclusive distribution agreement for its flagship anti-aging product, Premier Regenerative Complex---President Super Injection, in cooperation with Huajin China Investment Company（”Huajin China”), alongside the Board-approved divestiture of its non-core education business.

These strategic actions mark the Company’s formal transition into a commercialization acceleration phase within the high-end medical aesthetics sector.

Commercialization

Visionary Doubles Down on High-Margin Medical Aesthetics with US$12 Million Exclusive Agreement, Initiates Strategic Exit from Non-Core Businesses

Mon, 02 Mar 2026 09:30:00 -0400

HONG KONG, March 02, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“the Company”), a technology-driven multinational and biotechnology and healthcare-focused company, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited (“GV Hong Kong”), today announced the signing of a US$12 million exclusive distribution agreement for its flagship anti-aging product, Premier Regenerative Complex---President Super Injection, in cooperation with Huajin China Investment Company（”Huajin China”), alongside the Board-approved divestiture of its non-core education business.

These strategic actions mark the Company’s formal transition into a commercialization acceleration phase within the high-end medical aesthetics sector.

Commercialization

Visionary Holdings reports progress on $9 million sales contract

Tue, 24 Feb 2026 09:52:33 -0400

Visionary Holdings Inc. (NASDAQ: GV) announced continued execution of a commercial sales agreement valued at approximately $9 million through its subsidiary Visionary Health Technology Group Limited.
The agreement, signed in September 2025, is currently in the implementation stage with service activities underway. The company expects to achieve substantive execution milestones by the end of the first quarter of 2026, according to a press release.
The commercial scope includes the Premier Regenerative Complex product series for health management solutions and customized VIP health services featuring individualized medical evaluations and physician-guided programs.
"The continued execution of this agreement reflects our ability to effectively convert strategic

Visionary Holdings Announces Continued Progress of Approximately US$9 Million Sales Contract

Tue, 24 Feb 2026 09:50:00 -0400

Expects Significant Milestone Advancement by the End of March 2026
HONG KONG, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“the Company”), a technology-driven multinational enterprise, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited (“GV Hong Kong”), continued execution progress under its previously signed commercial sales agreement with a total contract value of approximately US$9 million.

The agreement, signed in September 2025, is currently in the implementation stage, with service activities underway. GV Hong Kong is working closely with its business partner to advance phased implementation efforts under the terms of

Visionary Holdings Announces Continued Progress of Approximately US$9 Million Sales Contract

Tue, 24 Feb 2026 09:50:00 -0400

Expects Significant Milestone Advancement by the End of March 2026
HONG KONG, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“the Company”), a technology-driven multinational enterprise, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited (“GV Hong Kong”), continued execution progress under its previously signed commercial sales agreement with a total contract value of approximately US$9 million.

The agreement, signed in September 2025, is currently in the implementation stage, with service activities underway. GV Hong Kong is working closely with its business partner to advance phased implementation efforts under the terms of

Visionary Holdings Announces Continued Progress of Approximately US$9 Million Sales Contract

Tue, 24 Feb 2026 09:50:00 -0400

Expects Significant Milestone Advancement by the End of March 2026
HONG KONG, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“the Company”), a technology-driven multinational enterprise, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited (“GV Hong Kong”), continued execution progress under its previously signed commercial sales agreement with a total contract value of approximately US$9 million.

The agreement, signed in September 2025, is currently in the implementation stage, with service activities underway. GV Hong Kong is working closely with its business partner to advance phased implementation efforts under the terms of

Visionary Holdings Announces Continued Progress of Approximately US$9 Million Sales Contract

Tue, 24 Feb 2026 09:50:00 -0400

Expects Significant Milestone Advancement by the End of March 2026
HONG KONG, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“the Company”), a technology-driven multinational enterprise, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited (“GV Hong Kong”), continued execution progress under its previously signed commercial sales agreement with a total contract value of approximately US$9 million.

The agreement, signed in September 2025, is currently in the implementation stage, with service activities underway. GV Hong Kong is working closely with its business partner to advance phased implementation efforts under the terms of

Visionary Holdings establishes three subsidiaries in China

Wed, 18 Feb 2026 09:36:06 -0400

Visionary Holdings Inc. (NASDAQ: GV) announced the establishment of three wholly owned subsidiaries in Qingdao, Wuxi, and Wuhu, China, through its subsidiary Visionary Health Technology Group Limited.
The subsidiaries will focus on localized market expansion, institutional partnerships, and sales execution for the company's regenerative medicine, cellular rejuvenation, and aesthetic treatment products. The three locations cover the Shandong Peninsula, Yangtze River Delta biomedical corridor, and Anhui regional healthcare market.
Each subsidiary will recruit professional sales teams to support hospitals, aesthetic clinics, and wellness institutions while developing strategic cooperation with regional medical providers and healthcare platforms. The subsidiaries will also support the rollout of

Visionary Holdings (Nasdaq: GV) Establishes Three Wholly Owned Subsidiaries in Qingdao, Wuxi and Wuhu, Advancing Commercial Expansion in China

Wed, 18 Feb 2026 09:31:00 -0400

HONG KONG, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (“GV” or the “Company”) (Nasdaq: GV), a technology-driven multinational enterprise, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited, has established three new regional wholly owned subsidiaries in Qingdao, Wuxi and Wuhu, China.

These subsidiaries are primarily dedicated to localized market expansion, institutional partnerships, and frontline sales execution for GV’s regenerative medicine, cellular rejuvenation, and aesthetic treatment product portfolio.

This development represents a meaningful operational milestone in GV’s transition from strategic platform buildout to coordinated multi-city commercial execution.

Visionary Holdings (Nasdaq: GV) Establishes Three Wholly Owned Subsidiaries in Qingdao, Wuxi and Wuhu, Advancing Commercial Expansion in China

Wed, 18 Feb 2026 09:31:00 -0400

HONG KONG, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (“GV” or the “Company”) (Nasdaq: GV), a technology-driven multinational enterprise, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited, has established three new regional wholly owned subsidiaries in Qingdao, Wuxi and Wuhu, China.

These subsidiaries are primarily dedicated to localized market expansion, institutional partnerships, and frontline sales execution for GV’s regenerative medicine, cellular rejuvenation, and aesthetic treatment product portfolio.

This development represents a meaningful operational milestone in GV’s transition from strategic platform buildout to coordinated multi-city commercial execution.

Visionary Holdings (Nasdaq: GV) Establishes Three Wholly Owned Subsidiaries in Qingdao, Wuxi and Wuhu, Advancing Commercial Expansion in China

Wed, 18 Feb 2026 09:31:00 -0400

HONG KONG, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (“GV” or the “Company”) (Nasdaq: GV), a technology-driven multinational enterprise, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited, has established three new regional wholly owned subsidiaries in Qingdao, Wuxi and Wuhu, China.

These subsidiaries are primarily dedicated to localized market expansion, institutional partnerships, and frontline sales execution for GV’s regenerative medicine, cellular rejuvenation, and aesthetic treatment product portfolio.

This development represents a meaningful operational milestone in GV’s transition from strategic platform buildout to coordinated multi-city commercial execution.

Visionary Holdings (Nasdaq: GV) Establishes Three Wholly Owned Subsidiaries in Qingdao, Wuxi and Wuhu, Advancing Commercial Expansion in China

Wed, 18 Feb 2026 09:31:00 -0400

HONG KONG, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (“GV” or the “Company”) (Nasdaq: GV), a technology-driven multinational enterprise, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited, has established three new regional wholly owned subsidiaries in Qingdao, Wuxi and Wuhu, China.

These subsidiaries are primarily dedicated to localized market expansion, institutional partnerships, and frontline sales execution for GV’s regenerative medicine, cellular rejuvenation, and aesthetic treatment product portfolio.

This development represents a meaningful operational milestone in GV’s transition from strategic platform buildout to coordinated multi-city commercial execution.

Visionary Holdings secures $450,000 debt financing via convertible note

Fri, 13 Feb 2026 16:32:56 -0400

Visionary Holdings Inc. (NASDAQ: GV) announced it received $450,000 in gross proceeds through a $500,000 senior secured convertible promissory note issued in December 2025 to an existing institutional investor.
The December 2025 note requires repayment by December 11, 2026, with interest accruing at the greater of prime rate plus 4.5% annually or 9% annually. Interest payments begin June 11, 2026, on a semi-annual basis. During default events, the interest rate increases to 18% annually.
The note converts into common stock at $1.44 per share at the investor's discretion, representing a lower conversion price compared to a previous $1.5 million note issued in

Visionary Holdings secures $450,000 debt financing via convertible note

Fri, 13 Feb 2026 16:32:56 -0400

Visionary Holdings Inc. (NASDAQ: GV) announced it received $450,000 in gross proceeds through a $500,000 senior secured convertible promissory note issued in December 2025 to an existing institutional investor.
The December 2025 note requires repayment by December 11, 2026, with interest accruing at the greater of prime rate plus 4.5% annually or 9% annually. Interest payments begin June 11, 2026, on a semi-annual basis. During default events, the interest rate increases to 18% annually.
The note converts into common stock at $1.44 per share at the investor's discretion, representing a lower conversion price compared to a previous $1.5 million note issued in